Rein Therapeutics Inc.
RNTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.06M
Close$
$0.13
79.9% downside
Current Fair Value
79.9% downsideOvervalued by 79.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.06 Million |
|---|---|
| Enterprise Value | $10.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.96 |
| Beta | 1.36 |
| Outstanding Shares | 30,354,647 |
Return
| Return on Equity | -90.14% |
|---|---|
| Return on Assets | -75.43% |
| Return on Invested Capital | -87.90% |
Valuation & Multiples
| P/E Ratio | -0.43 |
|---|---|
| PEG | 6.62 |
| Price to Sales | - |
| Price to Book Ratio | 0.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aileron Therapeutics Inc
10 employees
CEO: James Brian Windsor Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN...